Champlain Investment Partners LLC Cut Its Conmed Corporation (CNMD) Stake as Shares Rose

CONMED Corporation (NASDAQ:CNMD) LogoInvestors sentiment decreased to 1.18 in 2019 Q2. Its down 0.60, from 1.78 in 2019Q1. It dropped, as 20 investors sold CNMD shares while 64 reduced holdings. 32 funds opened positions while 67 raised stakes. 30.45 million shares or 20.13% less from 38.12 million shares in 2019Q1 were reported. Bnp Paribas Arbitrage Sa reported 4,226 shares. Moreover, Shell Asset Communications has 0.02% invested in CONMED Corporation (NASDAQ:CNMD). 72 were reported by Cullen Frost Bankers. Employees Retirement Association Of Colorado stated it has 0% of its portfolio in CONMED Corporation (NASDAQ:CNMD). Fisher Asset Management Lc reported 507,822 shares. 271,392 were accumulated by Barclays Public Limited Liability. Wendell David Associates has 0.03% invested in CONMED Corporation (NASDAQ:CNMD). Victory Capital, a Ohio-based fund reported 338,910 shares. Millennium Ltd Llc reported 0.2% stake. Panagora Asset Mgmt Incorporated holds 0.08% of its portfolio in CONMED Corporation (NASDAQ:CNMD) for 202,212 shares. Meeder Asset Management Incorporated has invested 0% in CONMED Corporation (NASDAQ:CNMD). Research Invsts owns 2.27M shares. American Century, Missouri-based fund reported 60,617 shares. Grantham Mayo Van Otterloo & Communication Ltd Liability Co holds 0.01% of its portfolio in CONMED Corporation (NASDAQ:CNMD) for 10,500 shares. Oak Ridge Investments Limited Liability Corp has invested 0.61% in CONMED Corporation (NASDAQ:CNMD).

Champlain Investment Partners Llc decreased its stake in Conmed Corporation (CNMD) by 5% based on its latest 2019Q2 regulatory filing with the SEC. Champlain Investment Partners Llc sold 87,336 shares as the company’s stock rose 9.52% . The institutional investor held 1.66 million shares of the electromedical & electrotherapeutic apparatus company at the end of 2019Q2, valued at $87.11 million, down from 1.75M at the end of the previous reported quarter. Champlain Investment Partners Llc who had been investing in Conmed Corporation for a number of months, seems to be less bullish one the $2.69 billion market cap company. The stock increased 1.53% or $1.43 during the last trading session, reaching $95.02. About 150,821 shares traded. CONMED Corporation (NASDAQ:CNMD) has risen 19.51% since October 12, 2018 and is uptrending. It has outperformed by 19.51% the S&P500.

Champlain Investment Partners Llc, which manages about $6.04B and $8.47B US Long portfolio, upped its stake in Nordson Corporation (NASDAQ:NDSN) by 799,057 shares to 966,785 shares, valued at $114.56 million in 2019Q2, according to the filing. It also increased its holding in Blue Buffalo Pet Products Inc by 1.13 million shares in the quarter, for a total of 2.16 million shares, and has risen its stake in Prosperity Bancshares Inc.(R) (NYSE:PB).

Analysts await CONMED Corporation (NASDAQ:CNMD) to report earnings on November, 7. They expect $0.56 earnings per share, up 21.74 % or $0.10 from last year’s $0.46 per share. CNMD’s profit will be $15.84M for 42.42 P/E if the $0.56 EPS becomes a reality. After $0.56 actual earnings per share reported by CONMED Corporation for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

More notable recent CONMED Corporation (NASDAQ:CNMD) news were published by: which released: “Quidel (QDEL) Q4 Earnings and Revenues Surpass Estimates – Nasdaq” on February 15, 2019, also with their article: “AMN Healthcare (AMN) Q4 Earnings Top, Revenues Lag Estimates – Nasdaq” published on March 08, 2019, published: “CONMED Announces Definitive Agreement to Acquire Buffalo Filter LLC – Business Wire” on December 13, 2018. More interesting news about CONMED Corporation (NASDAQ:CNMD) were released by: and their article: “Stocks That Hit 52-Week Highs On Tuesday – Benzinga” published on August 20, 2019 as well as‘s news article titled: “Myriad Genetics (MYGN) Q2 Earnings & Revenues Miss Estimates – Nasdaq” with publication date: February 06, 2019.

CONMED Corporation (NASDAQ:CNMD) Ratings Coverage

Among 3 analysts covering Conmed (NASDAQ:CNMD), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Conmed has $11000 highest and $92 lowest target. $100.33’s average target is 5.59% above currents $95.02 stock price. Conmed had 5 analyst reports since April 15, 2019 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, August 1 by Stifel Nicolaus. The rating was upgraded by Piper Jaffray to “Overweight” on Thursday, August 22. Barclays Capital maintained it with “Overweight” rating and $92 target in Monday, April 15 report.

CONMED Corporation (NASDAQ:CNMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.